In August 2023, Hengrui licensed the ex-Greater-China rights to its anti-TSLP antibody SHR-1905 to a newly formed company. Two months later, that company launched as Aiolos Bio with a $245 million Series A. In January 2024, GSK agreed to acquire Aiolos for $1 billion upfront and up to $400 million in regulatory milestones.

The sequence looked like a rapid revaluation of a China-origin asset. But the $1 billion was the acquisition price for Aiolos, not a payment to Hengrui. Public disclosures show Hengrui participating through the economics of its original license, while Aiolos’ equity holders were positioned to capture the immediate company-level premium.

Four months after the Aiolos sale was announced, Hengrui licensed the metabolic portfolio that became Kailera Therapeutics. This time, the terms included not only cash, milestones and royalties, but also an initial 19.9% fully diluted equity stake and a time-limited share of certain early partnering proceeds.

The useful comparison is not whether either deal was cheap. It is how each agreement connected Hengrui to different value events.

The right question is not simply how much equity the originator owns. It is which future event is expected to create the value—and whether the agreement gives the originator a claim on that event.

Value is created through events, not headline numbers

Signing, clinical de-risking, commercialization, an IPO, a partnership and a strategic sale are different value events. Upfront payments, milestones, royalties, equity, transaction-participation clauses and change-of-control terms each capture a different outcome. Diligence and reversion rights protect the downside if development stalls.

For investors, the disclosed “total deal value” is usually the least useful number. Separate paid cash, risk-adjusted contingent payments, retained rights and realizable equity value after dilution and liquidity constraints. A $5.725 billion milestone pool is not current value, just as an IPO-price mark is not realized cash.

Aiolos: a strategic buyer created a different kind of value

Aiolos was built around AIO-001, previously Hengrui’s SHR-1905. Hengrui had discovered the antibody, advanced it through early clinical development, and generated the preclinical, CMC and human data that supported its Phase 2-ready positioning. The program did not enter the NewCo as an early discovery asset.

Aiolos did not generate a new global Phase 2 efficacy readout before the GSK acquisition. It selected the asset from Hengrui’s pipeline, built a global product thesis and respiratory team, raised $245 million and created a company capable of advancing the program.

That made the program financeable and directly acquirable: GSK could obtain the rights, team and development plan in one transaction.

The price also reflected buyer-specific strategic value. GSK highlighted a validated TSLP target, potential six-month dosing and possible reach into severe asthma with low T2 inflammation, where treatment options remained limited. The $1 billion was therefore not a neutral value for SHR-1905; it included the asset’s strong fit with GSK.

Hengrui’s Hong Kong prospectus describes the license as including a $21.5 million upfront payment, more than $1 billion in potential development and sales milestones, and tiered royalties reaching up to double-digit percentages. When GSK acquired Aiolos, it also assumed responsibility for the milestones and royalties owed to Hengrui.

The public disclosures do not identify an Hengrui equity interest in Aiolos. Hengrui participated through its license economics, while Aiolos’ equity holders were positioned to capture the acquisition premium. This does not prove that Hengrui licensed too cheaply: Aiolos’ investors supplied capital and took risk, and GSK paid for strategic fit. It shows that strong asset economics do not automatically create exposure to a rapid company sale.

Kailera: rights matched to more than one future outcome

In May 2024, the company that became Kailera licensed three underlying metabolic molecules from Hengrui. They are being developed as four product candidates, including injectable and oral versions of ribupatide.

According to Kailera’s final IPO prospectus, Hengrui received:

• $100 million upfront and a $10 million technology-transfer payment;
• up to $200 million in clinical and regulatory milestones;
• up to $5.725 billion in commercial milestones;
• tiered royalties ranging from mid-single-digit to low-tens percentages, subject to customary reductions; and
• preferred shares representing 19.9% of Kailera on a fully diluted basis when issued.

Kailera launched publicly with a $400 million Series A financing commitment, later announced a $600 million Series B and completed an IPO. These were not payments to Hengrui, but its equity provided exposure to the company. Hengrui’s ownership fell from 19.9% at issuance to 13.6% before the base IPO, 9.3% after it and roughly 9% after the underwriters’ option was fully exercised.

At the $16 IPO price, Hengrui’s 11,511,853 shares had an indicated value of approximately $184 million. This was not cash, and realizable value would depend on lock-ups, liquidity and the later share price. It was nevertheless company-level participation not identified in the public Aiolos disclosures.

Kailera also included a less visible protection. If it had entered certain partnering relationships before November 15, 2025, Hengrui would have received specified percentages of the consideration based on timing. No qualifying transaction occurred and the right expired. The clause is still revealing: equity covered longer-term appreciation, while this term created a direct claim on early partnering proceeds.

Was Kailera a response to Aiolos?

The timing makes this plausible: GSK announced the Aiolos acquisition in January 2024, and Hengrui signed the Kailera agreement in May. Aiolos may have strengthened Hengrui’s negotiating case.

But this remains an inference. Hengrui has not publicly linked the structures, and the transactions differed: one antibody found a rapid strategic buyer, while a multi-asset obesity portfolio required repeated financing.

The documents support a narrower conclusion: Kailera matched Hengrui’s rights to more outcomes—drug progress, corporate growth and early partnering.

What investors and originators should take away

For investors, compare NewCo deals by economic exposure, not headline value or initial equity. Build an event-based waterfall: What has been paid? What remains contingent, over what time and probability? Which rights are retained? How will equity dilute, and what can make it realizable? The answers show who benefits under each outcome.

For biotech originators, choose rights around the NewCo’s intended path. If successive financings and an IPO are likely, equity, information and governance rights matter. If early partnering or a sale is plausible, transaction participation matters. For a commercialization path, royalties and sales milestones matter; against stalled execution, diligence and reversion rights matter.

The goal is not to maximize every term. Too many claims can make a NewCo harder to finance and reduce upfront value. The objective is to spend limited negotiating leverage on the most likely value events while leaving the company able to reach them.

Aiolos and Kailera are not simply better or worse deals. Aiolos became a focused company sold to a strategically aligned buyer. Kailera became a multi-asset company built for repeated financing and an IPO, with Hengrui holding claims across more outcomes.

For Chinese originators, the central question is precise: which event is expected to create the NewCo’s revaluation—and which term ensures that the originator participates?

Analysis based on public information available through July 26, 2026. All clinical programs discussed remain investigational. Transaction milestone amounts are contingent unless identified as paid. This article is for informational purposes and is not investment advice.